Pharma plant for sale in India: running factories and manufacturing units.
24 listings covering 23 plants are published here: 21 for sale and 3 for rent, across 4 states. Asking prices for drug-licensed plants run from ₹4 to ₹51 crore. 1 further sale listing is an FSSAI nutraceutical unit. One unit is offered for both sale and rent, so it appears twice. Each card states its licensed sections, certificate scope, areas, operating status and how far its information has been checked. Figures are seller-declared unless a card says otherwise.
Pharma plants and manufacturing units for sale or rent.
Filter by deal type, state, the sections you need approved, and budget. Sale and rent budgets are separate. Every card links to the full listing.
Running WHO-GMP oral solid unit with 400+ third-party clients
Revised Schedule M: Described by the seller as compliant.
Sterile injectable plant, small volume parenterals and ophthalmics
Revised Schedule M: Not stated on the listing page.
Carries a segregated beta-lactam injectable area with dedicated AHUs alongside the general section. Check the cross-contamination controls against your own product plan before valuing it.
Injectable and oral plant, eight licensed sections in a general and a beta-lactam block
Revised Schedule M: 4 of 8 sections upgraded, 4 in progress (seller).
WHO-GMP certificate under renewal; the renewal inspection has been carried out. Land is leased from the HP Department of Industries.
Two-unit tablet and oral liquid plant in Gokul Shirgaon MIDC, idle four years
Revised Schedule M: Not stated as a finding. The plant has been idle about four years.
In its last operating year the plant earned about ₹7 crore in conversion charges on products worth about ₹85 crore for its principal (seller declared). The cost and time to recommission an idle plant is the main valuation question.
WHO-GMP oral solid dosage plant, 600+ approved formulations
Revised Schedule M: Described by the seller as compliant.
Contract manufacturing facility, SIDCUL Pantnagar
Revised Schedule M: Not stated as a finding. The listing page lists the evidence to request.
Non-sterile only. Seller states there are no injectable, bulk drug or pesticide operations at site and that the Form 25 and Form 28 licences are active.
WHO-GMP unit commissioned 2023, five dosage sections
Revised Schedule M: Site master file revised in December 2025 (seller). A revised site master file describes the site; it is not an inspection finding.
Declared annual turnover about ₹24 crore, seller declared.
Running five-section unit in Kangra
Revised Schedule M: Site master file rebuilt to the revised standard, effective 4 February 2026 (seller). That documents the site; it is not an inspection finding.
Seller states Form 25 and Form 28 are valid to 18 September 2027.
Running tablet, capsule, liquid and dry-syrup unit
Revised Schedule M: Not stated as a finding. The listing page lists the evidence to request.
WHO-GMP scope covers tablets and capsules only. Liquid orals and dry syrup are licensed but sit outside the WHO-GMP certificate, which matters if you intend to export from those sections.
Running unit with 450+ approved formulations, asset and licence sale
Revised Schedule M: Described by the seller as compliant.
No WHO-GMP certificate stated. Budget for one if your export destination requires it.
Four-section GMP unit in Baddi, installed 2021
Revised Schedule M: Not stated as a finding.
GMP unit for tablets, capsules, liquids and external preparations
Revised Schedule M: Not stated as a finding.
Seller states no hazardous, toxic or hormonal products are handled at site. Confirm that against the product permission list and the cleaning validation records.
Four-section unit built 2020 to 2022 across four levels, QC lab with microbiology
Revised Schedule M: Gap assessment completed and upgradation plan filed (seller). A filed plan is not evidence of compliance.
Read the upgradation plan against your own product list before you value the unit.
Closed sterile injectable, beta-lactam and oral blocks inside one boundary wall
Revised Schedule M: Not applicable until re-licensed.
Read this one as premises plus re-licensing, not as a running unit. The seller states a bank liability of ₹6 crore against the asking price.
Tablet and capsule plant offered with its own marketing arm
Revised Schedule M: Described by the seller as compliant; read the certificate itself.
The drawings also show an ointment section, a beta-lactam sheet and a vacant floor that are not on the seller list of approved sections.
Four-section GMP unit near Roorkee, established 2020
Revised Schedule M: Not stated as a finding.
Four-section GMP unit in Roorkee, established 2008
Revised Schedule M: Not stated as a finding.
Running unit, 250+ formulations and 30 third-party clients
Revised Schedule M: Not stated as a finding. Seller describes a Schedule M design basis.
Licensed by the State drugs authority at Dharamshala. No WHO-GMP certificate disclosed.
Two-section unit, liquid orals and topical preparations
Revised Schedule M: Not stated as a finding.
Installed 2021, licence stated valid to 2027. Designed to WHO-GMP norms but certified GMP only (seller). No tablet or capsule section, so plan for a fresh section approval if oral solids are the target.
Small dual-licence unit: drug tablets alongside FSSAI nutraceutical lines
Revised Schedule M: Not stated as a finding.
Twenty-two FSSAI product lines sit alongside the drug licence. Check which of your own products can be made on which licence before you value the unit.
Nutraceutical tablet and capsule unit under FSSAI licence
Revised Schedule M: Not applicable. This is an FSSAI food licence, not a drug manufacturing licence.
Food-supplement products only. Making drugs here would need a separate Form 25 or Form 28 licence and section approvals.
Tablet and capsule unit on rent near NH-48, Rewari
Revised Schedule M: Upgraded in 2025 (seller). Not an inspection finding; ask for the latest State inspection report.
Seller states the unit was commissioned in 2018.
GMP unit on lease in Roorkee, 9,000 sq ft, tablets, capsules and liquid orals
Revised Schedule M: Not stated as a finding.
Quoted at ₹4,00,000 a month, with deposit and lock-in as per the lease terms. Reference LGP-RK-01.
The Una unit, offered on rent or loan licence
Revised Schedule M: Not stated as a finding.
Same unit as the ₹6.5 crore Una sale listing. The listing page notes that State industrial-area rules limit how much of a unit an allottee may rent out, so a loan licence on the owner premises is the likely route.
No published listing matches those filters. Listings priced on request stay in the results whatever the budget. Send the specification and we will tell you whether any unit we know of fits it.
How to read a card. Each card shows its information level and date: Site inspected on a date means Laafon has visited the site and reviewed its documents on that date; Seller-declared information means the figures come from the seller and no review is recorded yet. Turnover and other financial figures stay seller-declared on every card unless certified accounts have been reviewed. A seller statement, a revised site master file or a filed upgradation plan is not evidence of Revised Schedule M compliance; the latest State inspection report is the document to ask for. Rent and loan-licence options are also listed on the pharma unit for rent page.
Tell us the plant you are looking for
Your requirement is shared with a seller only with your agreement, and an NDA is available before any document changes hands.
Revised Schedule M is now being enforced.
Revised Schedule M was notified through G.S.R. 922(E) dated 28 December 2023 and applied to larger manufacturers from mid-2024.[1] Manufacturers with turnover up to ₹250 crore that applied for an extension had until 31 December 2025, and in November 2025 the Drugs Controller General of India asked State regulators to inspect units for compliance.[2] Earlier risk-based inspections had covered 905 units and led to 694 actions, from warning letters to stop-production orders and licence suspensions or cancellations.[3]
For a buyer, an unassessed unit carries an unpriced regulatory exposure. Whether that exposure stays with the seller or comes to you depends on how the deal is structured and licensed, so get a gap assessment and the latest inspection report before you make an offer. No further extension has been granted; this is the position as at 31 October 2026. The Revised Schedule M compliance dashboard tracks the detail.
Licences do not move automatically with the assets
A manufacturing licence in Form 25 or Form 28 is granted by the State Licensing Authority to a named licensee for specified premises and sections. Buying the land, building and machinery does not by itself put the licence in your name. Whether a deal needs a fresh licence, an amendment or a change-of-constitution filing depends on who the licensee is, how it is constituted, and whether you buy the assets or the licensee entity. Manufacturing licence applications are handled through the Online National Drugs Licensing System, which CDSCO runs with the State regulators.[4] Settle the structure early and confirm the route with the State authority, because the gap between possession and a licence in your name can leave a plant idle.
Five things that end a deal in diligence
- 01Certificate scope narrower than the plant. A WHO-GMP certificate covering two sections presented as whole-site certification.
- 02Areas that do not reconcile. Plot area, ground-floor footprint, floor-wise built-up area and the approved building drawings should agree. Check every unit conversion: 1 sq m is 10.764 sq ft.
- 03No Schedule M gap assessment or inspection report. A filed upgradation plan or a revised site master file is not evidence of compliance.
- 04Machinery under bank charge. Discovered late, it can strip the equipment out of the valuation you agreed.
- 05Seller-declared turnover with no filed accounts. Treat it as a hypothesis until the returns support it.
The full framework is in the pharma plant acquisition checklist.
Buy a running factory, buy a closed one, rent, or build.
The deciding variable is usually how soon you need a saleable batch and which markets you will supply, not the purchase price alone.
Scroll the table sideways on a phone.
| Route | Capital | Licence route | Main risk you carry |
|---|---|---|---|
| Buy a running unit | Seller asking prices on this page | Depends on licensee and deal structure; confirm with the State authority | Compliance history, undisclosed liabilities, staff retention |
| Buy a closed or idle unit | Purchase price plus recommissioning and upgrade | Usually a fresh licence with fresh section approvals | Upgrade cost found after possession instead of before the offer |
| Rent or loan licence | Monthly rent or conversion charges | Loan licence, or your own licence on leased premises where the rules allow | No asset ownership; you depend on the owner keeping the site compliant |
| Build greenfield | Varies widely with dosage forms and scale | Full fresh licensing, layout approval, validation from zero | Time, cost overrun, and validation spend before any revenue |
For greenfield numbers, use the pharma plant setup cost calculator or the pharma manufacturing plant cost breakdown.
Which route fits your constraint?
This is a starting position, not advice. Section approvals, product mix, destination rules and the seller's compliance history all move the answer.
What to check before you shortlist a manufacturing unit.
The categories a buyer's diligence team works through. A card's information level tells you which of these have been looked at for that listing.
- Form 25 and Form 28 licences, read against the originals, with the licensee, issuing State authority and validity date noted
- Section-wise approvals, because a licence naming tablets does not automatically carry capsules, liquid orals or a segregated beta-lactam area
- GMP and WHO-GMP certificate scope, section by section, since partial scope is often misread as whole-plant certification
- Product permission list, matched against the formulations you intend to run
- Inspection and enforcement history, including any stop-production order, show-cause notice or suspension on record, and the latest Revised Schedule M inspection report
- Revised Schedule M gap assessment across premises, flow, finishes and segregation, so the upgrade cost is known before the offer
- HVAC and cleanroom classification, with AHU count, filtration stages and whether qualification records exist and are current
- Purified water system: generation and storage capacity, loop design, sanitisation and monitoring records
- Machinery inventory: make, capacity, year, condition and qualification status, not a bare asset list
- Cleaning validation for the products actually made, read against the product permission list
- Title: freehold or industrial-estate lease, and what the lease permits on transfer or renting out
- Area reconciliation: plot, footprint and floor-wise built-up area against the approved drawings and the completion certificate
- Pollution control consents to establish and to operate, with validity and category
- Encumbrance, charge and litigation search, including any bank charge on plant and machinery
- Entity structure: an asset sale, a share transfer and a slump sale each lead to different licensing and liability consequences
- Reason for sale, stated plainly; a clean exit and a distressed exit are priced differently
- Client concentration: a unit with 400 third-party clients and one with 30 carry different revenue risk after handover
- Turnover and margin, treated as seller-declared until filed accounts support them
- Key staff, especially approved technical staff, whose departure can stall production while replacements are approved
- Working capital and creditors, separated from the asset price
Where the listed plants are.
Baddi, Paonta Sahib, Kala Amb, Una, Kangra
The deepest formulation cluster in North India. Baddi in District Solan carries the larger WHO-GMP oral solid and sterile plants on this page; Paonta Sahib, Kala Amb, Una and Kangra hold the smaller units.
Haridwar, Roorkee, Bhagwanpur, Rudrapur
The second northern cluster, built around the SIDCUL industrial estates, with running, closed and rental units on this page, plus one FSSAI nutraceutical unit.
Rewari and the NH-48 corridor
Closer to Delhi NCR, which suits companies that want manufacturing near their commercial team. The listing here is a rental.
Gokul Shirgaon MIDC, Kolhapur
Licensed by the Maharashtra FDA, so licensing timelines and inspection practice differ from the northern units. The listing is an idle two-unit plant, so recommissioning cost is the deciding question.
Gujarat is another major cluster. We have no published sale listing there at present.
List your plant confidentially.
Your identity and plant details are not published without your written consent. An NDA is available before any document changes hands.
Before you buy or sell a pharma factory.
Work through the numbers before you make an offer
-
Pharma plant acquisition checklist
The long-form due-diligence framework behind the checks above.
-
Revised Schedule M compliance dashboard
Score a unit against the inspection focus areas. Runs on your device; nothing is submitted.
-
Pharma manufacturing plant cost breakdown
Component-level capital costs by plant tier, and the factors that move them.
-
Pharma plant setup cost calculator
Enter sections, capacity, state and compliance standard to compare configurations.
-
Pharma unit for rent in India
The rental and loan-licence route.
- [1]Central Drugs Standard Control Organisation. Gazette Notifications: G.S.R. 922(E), Schedule M of the Drugs Rules 1945, 28 December 2023. New Delhi: Ministry of Health and Family Welfare. Available from: cdsco.gov.in Gazette Notifications. Accessed October 2026.
- [2]Press Trust of India. DCGI orders inspections of pharma units to ensure compliance with revised Schedule M norms. The Week; 10 November 2025 (secondary report of the DCGI letter of 7 November 2025). Available from: theweek.in. Accessed October 2026.
- [3]Ministry of Health and Family Welfare, Government of India. Steps taken to Prevent Sale of Adulterated Drugs. Press Information Bureau; 12 August 2025. Available from: pib.gov.in press release. Accessed October 2026.
- [4]Central Drugs Standard Control Organisation. Online National Drugs Licensing System (ONDLS). Ministry of Health and Family Welfare. Available from: statedrugs.gov.in. Accessed October 2026.
This page is technical and educational information for pharmaceutical professionals evaluating a manufacturing asset. It is not legal, regulatory, medical or investment advice. Listing figures come from each listing page and from the seller, and stay seller-declared until a card records a review. Indian statutory instruments, licence conditions and State practice change frequently, so confirm the current position with the relevant licensing authority and take your own professional advice before committing to a transaction.
Tell us the specification and we will tell you what fits.
State, sections, budget and timeline.